Oligooxopiperazine Scaffolds Stabilize Alpha-Helix Protein Binding

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current pharmaceuticals face limitations in targeting spatially extended protein surfaces due to the intrinsic conformational and chemical instabilities of peptides, which restrict their potential as drug reagents in molecular biology and drug discovery.

Innovation Solution

The development of nonpeptidic oligooxopiperazine scaffolds that mimic α-helix structures, obtained by linking neighboring amide nitrogen atoms in peptides with ethylene bridges, providing a chiral backbone that effectively discriminates between chiral protein pockets and stabilizes protein-protein interactions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional peptides are used to target protein-protein interactions, then they can potentially bind to protein surfaces, but their conformational and chemical instabilities limit their effectiveness and duration of action

Engineering Contradiction:

Improvebinding effectivenessVSAvoidconformational and chemical stability

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent changes the chemical parameters of the peptide backbone by replacing amide bonds with oxopiperazine linkages. This fundamental chemical modification transforms the peptide into a more stable oligooxopiperazine structure that resists proteolytic degradation and maintains conformational integrity, thereby resolving the contradiction between binding effectiveness and stability

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention creates a hybrid structure combining elements of traditional peptides (amino acid side chains, helical conformation) with non-peptidic components (oxopiperazine rings). This composite approach preserves the biological activity of peptides while incorporating the enhanced stability of synthetic cyclic structures

Inventive Principle:

Principle #40Composite materials

2Measurement precision

If small molecules are used as pharmaceuticals, then they can target enzymes or protein receptors with defined pockets, but they cannot target protein-protein interactions involving large contact areas with the required specificity

Engineering Contradiction:

Improvebinding specificityVSAvoidcontact area

Core Design Contradiction:

Measurement precisionVSArea of stationary object

Solution Approach 1:

The patent transitions from small molecule pharmacophores to extended oligomeric structures that span multiple dimensions. The oligooxopiperazines adopt helical conformations similar to α-helices, enabling them to cover larger surface areas and engage in extensive protein-protein interactions while maintaining specific binding through precisely positioned side chains

Inventive Principle:

Principle #17Another dimension (Dimensionality change)

Solution Approach 2:

The invention segments the binding interface into multiple discrete interaction points along the oligooxopiperazine chain. Each amino acid side chain can independently interact with complementary residues on the target protein, allowing the molecule to engage large contact areas through multiple localized specific interactions rather than a single binding event

Inventive Principle:

Principle #1Segmentation

3Ease of manufacture

If protein sub-domains are excised from the protein, then they can be isolated for study, but they rarely remain structured and lose their ability to specifically bind targets

Engineering Contradiction:

Improveisolation feasibilityVSAvoidstructural integrity

Core Design Contradiction:

Ease of manufactureVSStability of the object's composition

Solution Approach 1:

Rather than isolating and attempting to preserve native protein sub-domains, the patent synthesizes simplified copies that replicate only the essential structural features needed for binding. The oligooxopiperazines mimic the helical conformation and side chain arrangement of functional protein segments without requiring the full complexity of native structures, making them easier to produce and more stable

Inventive Principle:

Principle #26Copying

4Reliability

If peptides are used for drug discovery, then they can target protein interactions, but their poor cellular uptake limits their pharmacological utility

Engineering Contradiction:

Improvetargeting capabilityVSAvoidcellular uptake

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent changes the physicochemical parameters of the peptide by introducing cyclic oxopiperazine structures, which alter the molecule's permeability properties. This chemical transformation enables the compound to cross cell membranes more efficiently while retaining its ability to target protein interactions, thereby resolving the contradiction between targeting capability and cellular uptake

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS9624203B2Oligooxopiperazines and methods of making and using them

Publication Date: 2017.04.18 NEW YORK UNIV

AI summary

The present invention relates to oligooxopiperazines and their use. Methods for preparing oligooxopiperazines are also disclosed.